Semaglutide: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| (4 intermediate revisions by the same user not shown) | |||
| Line 73: | Line 73: | ||
</jmol>) to be attached without interfering with receptor binding. | </jmol>) to be attached without interfering with receptor binding. | ||
Interactions of the < | Interactions of the <jmol> | ||
<jmolLink> | |||
<script> | |||
moveto 1.0 { -864 363 349 132.79} 1354.39 0.0 0.0 {99.33772727272726 108.23119318181817 176.4468181818181} 129.71704236754204 {0 0 0} 0 0 0 3.0 0.0 0.0; | |||
script /scripts/10/1062575/Semaglutide_and_receptor/4.spt | |||
</script> | |||
<text>C-terminal part of semaglutide with the extracellular domain</text> | |||
</jmolLink> | |||
</jmol>include a hydrophobic patch (<jmol> | |||
<jmolLink> | <jmolLink> | ||
<script> | <script> | ||
| Line 126: | Line 134: | ||
<jmolLink> | <jmolLink> | ||
<script> | <script> | ||
moveto 1.0 { -685 -507 -522 122.57} 726.1 -1.39 -28.05 {109.93813084112149 120.8334205607477 156.36937383177562} 106.47485918259859 {0 0 0} 0 0 0 3.0 0.0 0.0; | |||
define current selected; | define current selected; | ||
select 7:P or 234:R or 241:R; | select 7:P or 234:R or 241:R; | ||
| Line 139: | Line 148: | ||
<jmolLink> | <jmolLink> | ||
<script> | <script> | ||
moveto 1.0 { -969 -113 -218 100.02} 1104.31 -7.13 -63.05 {109.93813084112149 120.8334205607477 156.36937383177562} 106.47485918259859 {0 0 0} 0 0 0 3.0 0.0 0.0; | |||
define current selected; | define current selected; | ||
select 9:P or 190:R; | select 9:P or 190:R; | ||
| Line 194: | Line 204: | ||
==Medical use of Semaglutide== | ==Medical use of Semaglutide== | ||
Semaglutide medications (Ozempic, Wegovy, and Rybelsus) have become extremely popular over time in managing weight loss and obesity. Originally developed as treatments for type 2 diabetes, medications such as Ozempic are now widely used for their ability to aid weight loss. As a GLP-1 receptor agonist (GLP-1 RA), semaglutide works by mimicking the effects of the GLP-1 hormone in the body. This action helps regulate the metabolic system, control appetite, and reduce calorie intake, leading to significant weight loss in many users. Semaglutide also slows gastric emptying, which prolongs the feeling of fullness after eating and further supports weight management. | Semaglutide medications (Ozempic, Wegovy, and Rybelsus) have become extremely popular over time in managing weight loss and obesity. A KFF poll conducted in May 2024 found that 1 in 8 respondents (adults in the United States) say that they have taken a GLP-1 agonist in the past <ref>Harris E. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable. JAMA. 2024;332(1):8. DOI:10.1001/jama.2024.10333</ref>. Originally developed as treatments for type 2 diabetes, medications such as Ozempic are now widely used for their ability to aid weight loss. As a GLP-1 receptor agonist (GLP-1 RA), semaglutide works by mimicking the effects of the GLP-1 hormone in the body. This action helps regulate the metabolic system, control appetite, and reduce calorie intake, leading to significant weight loss in many users. Semaglutide also slows gastric emptying, which prolongs the feeling of fullness after eating and further supports weight management. | ||
==Side effects== | ==Side effects== | ||
